2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2335

Antiendothelial Cell Antibodies in Juvenile Dermatomyositis: A Proteomics-Based Approach
Abstract Number: 2613

Antimalarial Drug Toxicities in Rheumatic Skin Disease Patients
Abstract Number: 1592

Antimalarial-Induced Cardiomyopathy in Systemic Lupus Erythematosus
Abstract Number: 2760

Antiphospholipid Syndrome Alliance for Clinical Trials & International Networking (APS ACTION) Clinical Database and Repository (“Registry”) Analysis: First and Recurrent Thrombosis Risk after 1201 Patient-Years of Follow-up
Abstract Number: 12

Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository Analysis: Pregnancy Outcomes Since Inception
Abstract Number: 8

Antiphospholipid Syndrome Leukocytes Demonstrate Increased Adhesive Potential: a Search for Novel Therapeutic Targets
Abstract Number: 760

Antisense Long Noncoding RNA HAND2-AS1 and OTUD6B-AS1 Have Important Roles in the Pathogenesis of Systemic Sclerosis
Abstract Number: 791

Aortic Dilatation in Patients with Large Vessel Vasculitis: A Longitudinal Case Control Study Using Positron Emission Tomography/Computed Tomography
Abstract Number: 2794

Apolipoprotein B Binds to Enolase-1 and Aggravates Inflammation in Rheumatoid Arthritis
Abstract Number: 689

Apolipoprotein L1 Risk Variants Associate with Hypertension and Nephritis Progression Despite Lower dsDNA Titers in Ghanaian Systemic Lupus Erythematous Patients
Abstract Number: 2838

Apoptotic Bodies Containing dsDNA Covalently Modified By Parvovirus B19 Non-Structural Protein NS1 Induce dsDNA Autoantibodies and End Organ Damage in Non-Autoimmune Mice
Abstract Number: 948

Application of a Diagnostic Algorithm to Identify Inflammatory Myopathy in Systemic Sclerosis
Abstract Number: 764

Application of a Novel Computational Approach to Identify New Targets and Pathways for Therapeutic Intervention in Scleroderma
Abstract Number: 1085

Application of Lupus Nephritis Quality Measures to Understand Gaps in Care for SLE
Abstract Number: 268

Applications of Salivary Gland Ultrasonography in Sjögren Syndrome and Sicca Symptoms: A Single Center Experience

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].